{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-068512","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.308376+00:00","generated_at":"2026-05-16T00:15:53.065590+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alkermes: FY2025 revenue $1.48B, GAAP EPS $1.43; 2026 guidance shows net loss from Avadel deal","bullets":["Total revenue $1.48B in 2025; proprietary net sales up ~9% to $1.18B; LYBALVI grew 22% in Q4.","GAAP net income $242M ($1.43 dil EPS) vs $367M in 2024; Q4 net income $49.3M.","Closed Avadel acquisition Feb 12, 2026; used $775M cash + $1.525B term loans; expects ~$150M inventory step-up expense.","2026 guidance: revenue $1.73-1.84B, GAAP net loss $(115)-$(135)M, adjusted EBITDA $370-410M.","Alixorexton Phase 3 for narcolepsy to start Q1 2026; advancing orexin pipeline for ADHD and fatigue."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-068512","json":"https://secwatch.observer/filing/0001193125-26-068512.json","markdown":"https://secwatch.observer/filing/0001193125-26-068512.md","text":"https://secwatch.observer/filing/0001193125-26-068512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/0001193125-26-068512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000119312526068512/alks-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:15:53.065590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}